Table 1.
Group Demographics and Clinical Variables
| Measure | Controls (n = 33) | ABS (n = 39) | REL (n = 65) | Group comparisons* |
|---|---|---|---|---|
| Age (years) | 46 (9) | 53 (9) | 51 (8) | CON < ABS, REL |
| Education (years) | 16.7 (2.6) | 14.6 (2.2) | 13.5 (1.9) | CON > ABS, REL; ABS > REL |
| Males (%) | 94 | 90 | 92 | |
| Caucasian (%) | 73 | 79 | 74 | |
| Days abstinent at AP2 | NA | 33 (9) | 33 (10) | |
| Days until relapse | NA | NA | 137 (80) | |
| Lifetime average drinks/month | 16 (14) | 182 (93) | 245 (145) | CON < ABS, REL; ABS < REL |
| Anti-relapse/craving medication (%) | NA | 15 | 22 | |
| Antidepressant s (%) | NA | 5 | 12 | |
| Psychiatric comorbidity (%) | NA | 23 | 49 | ABS < REL |
| Substance use disorder comorbidity (%) | NA | 21 | 15 | |
| Medical comorbidity (%) | NA | 44 | 54 | |
| Smokers (%) | NA | 51 | 62 | |
| FTND | NA | 5 (2) | 5 (2) | |
| Pack years | NA | 27 (19) | 28 (21) | |
| BDI | 4 (3) | 9 (8) | 10 (8) | CON < ABS, REL |
| STAI | 33 (7) | 47 (10) | 50 (13) | CON < ABS, REL |
| Body mass index | 25 (5) | 26 (5) | 27 (5) | |
| Number of previous AUD treatments (median) | NA | 2 | 3 | |
| Intracranial volume (cc) | 1596 (162) | 1599 (132) | 1575 (148) |
Note. ABS: Abstainers. AP2: Assessment point 2; BDI: Anti-relapse/craving medication: use of disulfiram, gabapentin and/or naltrexone; Beck Depression Inventory. CON: Controls. FTND: Fagerstrom Test for Nicotine Dependence. NA: not applicable. REL: Relapsers. STAI: State -trait Anxiety Inventory – Trait.
*
All listed group comparisons p < .05. Mean (SD).